Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: Blockade of arthritis severity by soluble Glycoprotein 130

Journal of Immunology

Volumn 171, Issue 6, 2003, Pages 3202-3209

  Nowell, Mari A ^a   Richards, Peter J ^a   Horiuchi, Sankichi ^b   Yamamoto, Naoki ^b   Rose John, Stefan ^c   Topley, Nicholas ^d   Williams, Anwen S ^d   Jones, Simon A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c UNIVERSITY OF KIEL   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CORTICOSTEROID; GLYCOPROTEIN P; HYBRID PROTEIN; HYPERINTERLEUKIN 6; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; SOLUBLE GLYCOPROTEIN GP 130; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FIBROBLAST; HISTOPATHOLOGY; LEUKOCYTE MIGRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; SYNOVIUM;

EID: 0042834261     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.6.3202     Document Type: Article

References (52)

1. Houssiau, F. A., J. Devogelaer, J. Van Damme, C. Nagant de Deuxchaisnes, and J. Van Snick. 1988. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31:784.
2. Guerne, P. A., B. L. Zuraw, J. H. Vaughan, D. A. Carson, and M. Lotz. 1989. Synovium as a source of interleukin 6 in vitro. J. Clin. Invest. 83:585.
3. Manicourt, D. H., R. Triki, K. Fukuda, J. P. Devogelaer, C. Nagant de Deuxchaisnes, and E. J. M. A. Thonar. 1993. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis. Arthritis Rheum. 36:490.
4. Arvidson, N. G., B. Gudbjornsson, L. Elfman, A. C. Ryden, T. H. Tötterman, and R. Hällgren. 1994. Circadian rhythms of serum interleukin-6 in rheumatoid arthritis. Rheum. Dis. 53:521.
5. Desgeorges, A., C. Gabay, P. Silacci, D. Novick, P. Roux-Lombard, G. Grau, J. M. Dayer, T. Vischer, and P. A. Guerne. 1997. Concentrations and origins of soluble interleukin 6 receptor-α in serum and synovial fluid. J. Rheumatol. 24:1510.
6. Van de Loo, F. A., S. Kuiper, F. H. van Enckevort, O. J. Antz, and W. B. van der Berg. 1997. Interleukin-6 reduces cartilage destruction during experimental arthritis: a study in interleukin-6-deficient mice. Am. J. Pathol. 151:177.
7. Ji, H., A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis, and C. Benoist. 2002. Critical roles for interleukin-1 and tumor necrosis factor-α in antibody-induced arthritis. J. Exp. Med. 196:77.
8. Alonzi, T., E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187:461.
9. Oshima, S., Y. Saeki, T. Mima, M. Sasai, K. Nishioka, S. Nomura, M. Kopf, Y. Katada, T. Tanaka, M. Suemura, and T. Kishimoto. 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. USA 95:8222.
10. Boe, A., M. Baiocchi, M. Carbonatto, R. Papoian, and O. Serlupi-Crescenzi. 1999. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11:1057.
11. Sasai, M., Y. Saeki, S. Oshima, K. Nishioka, T. Mima, T. Tanaka, Y. Katada, K. Yoshizaki, M. Suemura, and T. Kishimoto. 1999. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 42:1635.
12. De Hooge, A. S. K., F. A. J. van de Loo, O. J. Arntz, and W. B. van den Berg. 2000. Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am. J. Pathol. 157:2081.
13. Madhok, R., A. Crilly, J. Watson, and H. A. Capell. 1993. Serum interleukin-6 levels in rheumatoid arthritis: correlations with clinical and laboratory indexes of disease activity. Ann. Rheum. Dis. 52:232.
14. Keul, R., P. C. Heinrich, G. Müller-Newen, K. Muller, and P. Woo. 1998. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 10:729.
15. Wendling, D., A. Racadote, and J. Wijdenes. 1993. Treatment of severe rheumatoid arthritis by an anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20:259.
16. Takagi, N., M. Mihara, Y. Moriya, N. Nishimoto, K. Yoshizaki, T. Kishimoto, Y. Takeda, and Y. Ohsugi. 1998. Interleukin-6 receptor blockage ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41:117.
17. Imazeki, I., H. Saito, M. Hasegawa, H. Shinkura, T. Kishimoto, and Y. Oshugi. 1998. IL-6 functions in cynomolgus monkeys blocked by a humanized antibody to human IL-6 receptor. Int. J. Immunopharmacol. 20:345.
18. Mihara, M., M. Kotoh, N. Nishimoto. Y. Oda, E. Kumagai, N. Takagi, K. Tsunemi, Y. Ohsugi, T. Kishimoto, K. Yoshizaki, and Y. Takeda. 2001. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin. Immunol. 98:319.
19. Choy, E. H. S., D. A. Isenberg, T. Garrod, S. Farrow, Y. Ioannou, H. Bird, N. Cheung, B. Williams, B. Hazleman, R. Price, et al. 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. 46:3143.
20. Jones, S. A., S. Horiuchi, N. Topley, N. Yamamoto, and G. M. Fuller. 2001. The soluble interleukin-6 receptor: mechanisms of production and implications in disease. FASEB J. 15:43.
21. Jones, S. A., and S. Rose-John. 2002. Soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim. Biophys. Acta 1592:251.
22. Heinrich, P. C., I. Behrmann, G. Muller-Newen, F. Schaper, and L. Graeve. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334:297.
23. Kotake, S., K. Sato, K. J. Kim, N. Takahashi, N. Udagawa, I. Nakamura, A. Yamaguchi, T. Kishimoto, T. Suda, and S. Kashiwazaki. 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11:88.
24. Mihara, M., Y. Moriya, T. Kishimoto, and Y. Oshugi. 1995. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br. J. Rheumatol. 34:321.
25. Franchimont, N., S. Rydziel, A. M. Delaney, and E. Canalis. 1997. Interleukin-6 and its soluble receptor cause a marked induction of collagenase 3 expression in rat osteoblastic cultures. J. Biol. Chem. 272:12144.
26. Flannery, C. R., C. B. Little, C. E. Hughes, C. L. Curtis, B. Caterson, and S. A. Jones. 2000. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol. 19:549.
27. Hurst, S. M., T. S. Wilkinson, R. M. McLoughlin, S. Jones, S. Horiuchi, N. Yamomoto, S. Rose-John, G. M. Fuller, N. Topley, and S. A. Jones. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14:705.
28. Fischer, M., J. Goldschmitt, C. Peschel, J. P. G. Brakenhoff, K.-J. Kallen, A. Wollmer, J. Grötzinger, and S. Rose-John. 1997. A bioactive designer cytokine for the hematopoietic progenitor cell expansion. Nat. Biotechnol. 15:142.
29. Dayer, I. M., S. M. Krane, R. Graham, D. R. Russell, and D. R. Robinson. 1976. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc. Natl. Acad. Sci. USA 73:945.
30. Horiuchi, S., Y. Koyanagi, Y. Zhou, H. Miyamoto, Y. Tanak, M. Waki, A. Matsumoto, M. Yamamoto, and N. Yamamoto. 1994. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol. 24:1945.
31. Horiuchi, S., W. Ampofo, Y. Koyanagi, A. Yamashita, M. Waki, A. Matsumoto, and M. Yamamoto. 1998. High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukemia/HTLV-1-associated myelopathy. Immunology 95:360.
32. Li, F. K., A. Davenport, R. Robson, P. Loetscher, R. Rothlein, J. D. Williams, and N. Topley. 1998. Leukocyte migration across human peritoneal mesothelial cells is dependent on directed chemokine secretion and ICAM-1 expression. Kidney Int. 54:2170.
33. Jostock, T., J. Müllberg, S. Özbek, R. Atreya, G. Blinn, N. Voltz, M. Fischer, M. Neurath, and S. Rose-John. 2001. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268:160.
34. Robak, T., A. Gladalska, H. Stepien, and E. Robak. 1998. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Med. Inflamm. 7:347.
35. Jones, S. A., D. Novick, S. Horiuchi, N. Yamamoto, A. J. Szalai, and G. M. Fuller. 1999. C-reactive protein: a physiological activator of IL-6 receptor shedding. J. Exp. Med. 189:599.
36. Marin, V., F. A. Montero-Julian, S. Gres, V. Boulay, P. Bongrand, C. Farnarier, and G. Kaplanski. 2001. The IL-6-soluble IL-6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J. Immunol. 167:3445.
37. Modur, V., Y. Li, G. A. Zimmerman, S. M. Prescott, and T. M. McIntyre. 1997. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble IL-6 receptor α. J. Clin. Invest. 100:2752.
38. Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, et al. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315.
39. Klouche, M., S. Rose-John, W. Schmiedt, and S. Bhakdi. 2000. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation and proliferation. Circulation 101:1799.
40. Matsumiya, T., T. Imaizumi, K. Fujimoto, X. Cui, T. Shibata, W. Tamo, M. Kumagai, K. Tanji, H. Yoshida, H. Kimura, and K. Datoh. 2001. Soluble interleukin-6 receptor α inhibits the cytokine-induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp. Cell Res. 269:35.
41. Oh, J. W., N. J. Van Wagoner, S. Rose-John, and E. N. Benveniste. 1998. Role of IL-6 and the soluble receptor in inhibition of VCAM-1 gene expression. J. Immunol. 161:4992.
42. Wipke, B. T., and P. M. Allen. 1998. Essential role for neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J. Immunol. 167:1601.
43. Pope, R. M. 2002. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. 2:1.
44. Baggiolini, M. 1998. Chemokines and leukocyte traffic. Nature 392:565.
45. Gong, J., L. G. Ratkay, J. D. Waterfield, and I. Clark-Lewis. 1997. An antagonist of monocyte chemoattractant protein-1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med. 186:131.
46. Suzuki, H., K. Yasukawa, T. Saito, M. Narazaki, A. Hasegawa, T. Taga, and T. Kishimoto. 1993. Serum-soluble interleukin-6 receptor in MRL-lpr mice is elevated with age and mediates the interleukin-6 signal. Eur. J. Immunol. 23:1078.
47. Teague, T. K., P. Marrack, J. W. Kappler, and A. T. Vella. 1997. IL-6 rescues resting mouse T-cells from apoptosis. J. Immunol. 158:5791.
48. Atreya, R., J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6:583.
49. Salmon, M., D. Scheel-Toellner, A. P. Huissoon, D. Pilling, N. Shamsaadeen, A. D. D'Angeac, P. A. Bacon, P. Emery, and A. Akbar. 1997. Inhibition of T-cell apoptosis in rheumatoid synovium. J. Clin. Invest. 99:439.
50. Atsumi, T., K. Ishihara, D. Kamimura, H. Ikushima, T. Ohtani, S. Hirota, H. Kobayashi, S.-J. Park, Y. Saeki, Y. Kitamura, and T. Hirano. 2002. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196:979.
51. Peters, M., S. Jacobs, M. Ehlers, P. Vollmer, J. Müllberg, E. Wolf, G. Brem, K.-H.M. zum Büschenfelde, and S. Rose-John. 1996. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med. 183:1399.
52. Tanaka, M., M. Kishimura, S. Ozaki, F. Osakada, H. Hashimoto, M. Okubo, M. Murakami, and K. Nakao. 2000. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J. Clin. Invest. 106:137.